BASEL, SWITZERLAND--(Marketwire - Nov 29, 2011) -

Basilea Pharmaceutica AG / Extraordinary general meeting of shareholders of Basilea Pharmaceutica Ltd. . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, November 29, 2011 - Basilea Pharmaceutica Ltd. (SIX: [ BSLN ]) shareholders elect additional members to the board of directors.

Today the shareholders of Basilea elected Dr. Thomas M. Rinderknecht, Mr. Domenico Scala and Dr. Thomas Werner as additional members to the board of directors for a term of three years each.

Basilea's board of directors now comprises eight members: Mr. Werner Henrich, Mr. Hans-Beat Gürtler, Prof. Daniel Lew, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Claude Schreiner, Mr. Steven D. Skolsky and Dr. Thomas Werner. Mr. Werner Henrich and Mr. Hans-Beat Gürtler were confirmed by the newly constituted board as chairman and vice-chairman of the board of directors, respectively.

49.66% of the total share capital of the company was represented at the extraordinary general meeting of shareholders.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: [ BSLN ]). Basilea Pharmaceutica International Ltd.'s fully integrated research and development operations are focused on antibiotics, antifungals and oncology drugs, as well as on the development of dermatology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.

Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, in Denmark, Finland, France, Germany, Norway, Switzerland and the United Kingdom and has appointed distributors for Toctino® in other selected European markets, Canada, Israel, Mexico and the Republic of Korea. A phase III clinical program on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S.

For its phase III compound isavuconazole, a potential best-in-class azole antifungal for the treatment of life-threatening invasive fungal infections, the company has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc.

In addition, Basilea is developing ceftobiprole, a late-stage novel anti- MRSA (methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin antibiotic, for the first-line treatment of potentially life-threatening resistant bacterial infections. Ceftobiprole has a broad coverage of both Gram- positive bacteria, including MRSA, and many clinically important Gram- negative bacteria such as Pseudomonas spp.

Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram- negative infections, and the oncology drug BAL101553 for the treatment of drug- resistant cancers are in phase I clinical testing.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward- looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from [ www.basilea.com ].

--- End of Message ---

Basilea Pharmaceutica AG Grenzacherstrasse 487
P.O Box Basel Switzerland

Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München;

Press release (PDF): [ http://hugin.info/134390/R/1567439/486917.pdf ]

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1567439]